How estrogen blocks signals that make bone-resorbing cells break down bone
Antagonism of RANKL signaling by estrogen in osteoclasts
['FUNDING_R01'] · UNIV OF ARKANSAS FOR MED SCIS · NIH-11286803
This work looks at how estrogen helps prevent bone loss after menopause by stopping signals that make bone-resorbing cells more active.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF ARKANSAS FOR MED SCIS (nih funded) |
| Locations | 1 site (LITTLE ROCK, UNITED STATES) |
| Trial ID | NIH-11286803 on ClinicalTrials.gov |
What this research studies
Researchers will study bone-resorbing cells in the lab to see how estrogen changes their energy use and survival. They will examine how a molecule called RANKL boosts mitochondrial activity and how estrogen blocks that effect, focusing on a mitochondria-associated protein called ECSIT and on cellular NAD+ levels. The team will run cellular and molecular experiments measuring mitochondrial respiration, ATP production, and signs of mitochondria-driven apoptosis in osteoclast progenitors. Results may point to ways to protect bone without systemic hormone replacement.
Who could benefit from this research
Good fit: People who are postmenopausal and experiencing bone loss or osteoporosis are the most relevant group for this research.
Not a fit: People with bone loss due to genetic disorders, certain cancers, or causes unrelated to estrogen may not directly benefit from these findings.
Why it matters
Potential benefit: If successful, this work could point to new treatments that protect bone by mimicking estrogen’s effects on bone-resorbing cells without full hormone therapy.
How similar studies have performed: Previous research shows estrogen reduces osteoclast activity and bone loss, but targeting mitochondrial pathways and the ECSIT protein is a newer, largely preclinical approach.
Where this research is happening
LITTLE ROCK, UNITED STATES
- UNIV OF ARKANSAS FOR MED SCIS — LITTLE ROCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALMEIDA, MARIA JOSE — UNIV OF ARKANSAS FOR MED SCIS
- Study coordinator: ALMEIDA, MARIA JOSE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.